Cosan (CSAN3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Managed/adjusted EBITDA for Q4 2025 was R$7.8 billion, with full-year managed EBITDA at R$26.5 billion, both declining year-over-year due to weaker Raízen and Radar performance.
Adjusted net loss for Q4 2025 was R$713 million, with a full-year adjusted net loss of R$4.0 billion, mainly from lower equity income and non-recurring impairments at Raízen.
Dividends and interest on equity received totaled R$479 million in Q4 and R$2.6 billion for the year, both down from 2024 due to absence of Moove dividends and lower Compass contribution.
Strengthened capital structure through a R$10.5 billion equity raise, new strategic shareholders, and debt prepayments of R$6.2 billion in early 2026.
Ended 2025 amid a challenging macroeconomic environment, focusing on deleveraging and operational resilience.
Financial highlights
Expanded net debt decreased to R$9.8 billion at year-end, a reduction of nearly R$14 billion year-over-year, driven by asset sales and capital injection.
Debt Service Coverage Ratio (DSCR) closed the year at 0.9x, reflecting high financial expenses and lower dividends.
Average cost of debt at quarter end was CDI + 0.97%, with average maturity stable at 5.8 years.
Year-end cash position was R$16.0 billion.
Consolidated net revenue was R$40.4 billion in 2025, down 8% year-over-year.
Outlook and guidance
Focus remains on further deleveraging, capital structure optimization, and advancing strategic projects, including a planned secondary public equity offering at Compass.
Ongoing commitment to efficiency gains, capital discipline, and sustainability initiatives.
Forward-looking statements are subject to risks, including economic, political, and regulatory uncertainties in Brazil.
Latest events from Cosan
- Net loss reached R$1.8B, EBITDA fell 30%, but net debt dropped to R$17.5B after asset sales.CSAN3
Q1 20258 Jul 2026 - EBITDA rose, net income fell, and management changes and acquisitions shaped the quarter.CSAN3
Q3 20242 Jul 2026 - EBITDA rose 15% to R$7.1bn, net loss narrowed, and capital discipline remained strong.CSAN3
Q2 20242 Jul 2026 - Net revenue rose 11%, but large impairments led to a R$9.4 billion net loss in 2024.CSAN3
Q4 20242 Jul 2026 - Net loss narrowed to R$1.6 billion, with strong EBITDA and major deleveraging actions.CSAN3
Q1 202622 May 2026 - EBITDA and net income declined, but R$10.5 billion equity raised improved capital structure.CSAN3
Q3 20253 Feb 2026 - EBITDA fell to R$6.0bn, net loss widened, and leverage rose to 3.4x as segment results diverged.CSAN3
Q2 20253 Feb 2026